Trifecta GT

Designed for Optimal
SAVR Outcomes

The “Tri” in the Trifecta valve with Glide Technology (GT) and Linx anticalcification (AC) technology was inspired by its three design features—hemodynamics, durability, and implantability—all of which can deliver top performance for both implanting physicians and their patients. And the Trifecta GT valve is designed especially for a minimally invasive approach with its smaller, more streamlined valve holder, screw-in handle, and smooth delivery.

In addition, the Trifecta GT valve offers a single-cut quick release holder for greater efficiency.

The Trifecta GT valve further provides protection using Linx AC technology, a valve treatment that resists calcification1,* by:

  • Reducing free aldehydes2,3
  • Extracting lipids4
  • Minimizing cholesterol uptake5
  • Stabilizing leaflet collagen5

*No clinical data are currently available evaluating the long-term impact of anticalcification tissue treatment in humans.

 


Expansive, Externally Mounted
Leaflet Design.

 

AP2947045-WBO Rev. A

References
  1. Shen M, et al. Effect of ethanol and ether in the prevention of calcification of bioprostheses. AnnThorac Surg. 2001;71(Suppl. 5): S413-S416. doi:org/10.1016/S0003-4975(01)02521-8.
  2. Kelly SJ, et al. Biocompatibility and calcification of bioprosthetic heart valves. Presented at the Society for Biomaterials, Sixth World Biomaterials Congress Transaction. May 2000:1353.
  3. Frater RWM, et al. Chapter 8. In: Gabbay, S, Wheatley DJ, eds. Advances in Anticalcific and Antidegenerative Treatment of Heart Valve Bioprostheses. 1st ed. Austin: Silent Partners, Inc; 1997:105-113.
  4. Vyavahare N, et al. Prevention of bioprosthetic heart valve calcification by ethanol preincubation. Circulation. 1997:95;479-488. doi.org/10.116/01.CIR.95.2.479.
  5. Vyavahare NR et al. Prevention of calcification of glutaraldehyde-crosslinked porcine aortic cusps by ethanol preincubation: mechanistic studies of protein structure and water-biomaterial relationships. J Biomed Mater Res. 1998;40(4):577-585. doi: org/10.1002/(SICI)1097-4636(19980615)40:4<577::AID-JBM9>3.0.CO;2-C.
     

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.